发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition 诺华以15.3亿美元收购Fougera制药公司，山德士成为全球最大的非专利皮肤科公司
Pharmadeals Review Pub Date : 2012-11-05 DOI: 10.3833/pdr.v2012i5.1741
Heather Cartwright
{"title":"Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i5.1741","DOIUrl":"https://doi.org/10.3833/pdr.v2012i5.1741","url":null,"abstract":"Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78162661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Celgene Gains Buyout Option with VentiRx Cancer Collaboration Celgene获得VentiRx癌症合作的收购选择权
Pharmadeals Review Pub Date : 2012-10-27 DOI: 10.3833/PDR.V2012I10.1825
Heather Cartwright
{"title":"Celgene Gains Buyout Option with VentiRx Cancer Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I10.1825","DOIUrl":"https://doi.org/10.3833/PDR.V2012I10.1825","url":null,"abstract":"Celgene has formed a global collaboration with the virtual company VentiRx Pharmaceuticals to fund Phase II trials of VentiRx’s TLR8 (Toll-like receptor 8) agonist VTX-2337 in ovarian and head-and-neck cancers. Celgene will provide US$35 M upfront for further development of the drug through predefined clinical endpoints and in return retains an exclusive option to acquire VentiRx at a predetermined price. VentiRx is also eligible to receive additional funding during the option period, including a potential equity investment by Celgene. VentiRx in-licensed Array BioPharma’s TLR8 programme in 2007.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"100 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91455895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K 杨森生物技术授权安斯泰来口服JAK抑制剂ASP015K在日本以外的权利
Pharmadeals Review Pub Date : 2012-10-17 DOI: 10.3833/PDR.V2012I10.1821
Heather Cartwright
{"title":"Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I10.1821","DOIUrl":"https://doi.org/10.3833/PDR.V2012I10.1821","url":null,"abstract":"In a bid to strengthen its autoimmune disease franchise, Johnson & Johnson’s Janssen Biotech has licensed worldwide rights, excluding Japan, to develop and commercialise Astellas Pharma’s ASP015K, a Janus kinase (JAK) inhibitor in Phase IIb development for moderate-to-severe rheumatoid arthritis (RA). J&J already markets the anti-TNF-alpha (anti-tumour necrosis factor alpha) agents Remicade® (infliximab) and Simponi® (golimumab). Pfizer’s tofacitinib is poised to be the first JAK inhibitor to be approved for the treatment of RA with a regulatory decision expected from the US FDA in November 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74437881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bayer and Evotec Collaborate to Develop Three Endometriosis Drug Candidates 拜耳和Evotec合作开发三种子宫内膜异位症候选药物
Pharmadeals Review Pub Date : 2012-10-15 DOI: 10.3833/pdr.v2012i10.1820
Heather Cartwright
{"title":"Bayer and Evotec Collaborate to Develop Three Endometriosis Drug Candidates","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i10.1820","DOIUrl":"https://doi.org/10.3833/pdr.v2012i10.1820","url":null,"abstract":"Bayer Pharma and Evotec have entered into a 5-year partnership aimed at developing three clinical candidates for the treatment of endometriosis. Both companies will contribute drug targets and will be jointly responsible for early research and preclinical characterisation. Bayer will then undertake any subsequent clinical development and commercialisation. Bayer already markets the progesterone receptor agonist Visanne® (dienogest) for the treatment of endometriosis and the deal could help strengthen the company’s women’s healthcare business in the long term.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86981156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition 巴斯夫收购普罗诺瓦生物制药，力争在欧米伽-3原药市场占据领先地位
Pharmadeals Review Pub Date : 2012-10-12 DOI: 10.3833/PDR.V2012I12.1858
Heather Cartwright
{"title":"BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I12.1858","DOIUrl":"https://doi.org/10.3833/PDR.V2012I12.1858","url":null,"abstract":"In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M). The deal follows BASF’s May 2012 acquisition of Equateq, a UK-based manufacturer of concentrated omega-3 fatty acids.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74812742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal 初创公司耐受性制药以1.3亿美元的交易获得了人类公司Btk项目的许可
Pharmadeals Review Pub Date : 2012-10-05 DOI: 10.3833/PDR.V2012I5.1740
Heather Cartwright
{"title":"Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1740","DOIUrl":"https://doi.org/10.3833/PDR.V2012I5.1740","url":null,"abstract":"In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases. Interestingly, MannKind retains the right to reacquire the Btk assets at prespecified terms up to 60 days after completion of the first Phase I study.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85692415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions Forma Therapeutics和勃林格殷格翰合作靶向肿瘤相关蛋白-蛋白相互作用
Pharmadeals Review Pub Date : 2012-10-02 DOI: 10.3833/PDR.V2012I2.1677
Heather Cartwright
{"title":"Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1677","DOIUrl":"https://doi.org/10.3833/PDR.V2012I2.1677","url":null,"abstract":"Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87412662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance Forma Therapeutics和Janssen Biotech联手建立7亿美元药物发现联盟，瞄准肿瘤代谢
Pharmadeals Review Pub Date : 2012-10-02 DOI: 10.3833/PDR.V2012I2.1676
Heather Cartwright
{"title":"Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1676","DOIUrl":"https://doi.org/10.3833/PDR.V2012I2.1676","url":null,"abstract":"Forma Therapeutics has secured another big pharma deal by forming a cancer drug discovery alliance with Johnson & Johnson’s Janssen Biotech. Forma will discover and develop drugs against a panel of tumour metabolism targets and could receive up to US$700 M in project funding and milestone payments plus royalties. In a first for the company and contingent upon the achievement of certain milestones during the initial phase of the collaboration, Forma has an option to co-develop and retain North American rights to one of the collaboration programmes, to be selected by Janssen.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"296 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73201301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics Xenon和Genentech合作开发疼痛治疗和伴随诊断
Pharmadeals Review Pub Date : 2012-10-02 DOI: 10.3833/PDR.V2012I2.1678
Heather Cartwright
{"title":"Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1678","DOIUrl":"https://doi.org/10.3833/PDR.V2012I2.1678","url":null,"abstract":"Canadian Xenon Pharmaceuticals has formed its sixth major partnership by agreeing to collaborate with Roche’s Genentech on the discovery and development of novel compounds and companion diagnostics for the potential treatment of pain. The agreement is interesting in that Genentech will gain an exclusive licence to compounds and a non-exclusive licence to diagnostics for future development and commercialisation. The deal is potentially worth up to US$646 M to Xenon in research, development and commercialisation milestones for multiple products and indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85739775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib 百特通过授权Onconova Therapeutics的Rigosertib的欧洲权利扩大其肿瘤产品线
Pharmadeals Review Pub Date : 2012-09-27 DOI: 10.3833/PDR.V2012I9.1811
Heather Cartwright
{"title":"Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1811","DOIUrl":"https://doi.org/10.3833/PDR.V2012I9.1811","url":null,"abstract":"In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib. The drug candidate is currently in Phase III development for myelodysplastic syndromes, for which it has been granted Orphan Drug Designation in the US and Europe, and is the subject of a Phase II/III study in pancreatic cancer. Baxter, which has an existing US$50 M equity position in Onconova, also has the option to develop rigosertib in additional indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89039787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信